



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6 October 2023
EMA/CVMP/452705/2023
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion¹ (post-authorisation)

CircoMax Myco

Common name: Porcine circovirus vaccine (inactivated, recombinant) and Mycoplasma hyopneumoniae vaccine (inactivated)

On 5 October 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal products CircoMax and CircoMax Myco. The marketing authorisation holder for these veterinary medicinal products is Zoetis Belgium.

The variation is to add the option of administering CircoMax and CircoMax Myco intramuscularly, using needle-free devices. Some editorial changes to the product information are proposed. The name of the marketing authorisation holder is corrected from Zoetis Belgium SA to Zoetis Belgium.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

